The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

Pacylex Pharmaceuticals Publishes a New Myristoylation Inhibitor Mechanism of Anti-Cancer Activity in Molecular Cancer Therapeutics ...

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) led a global study that identified ...

Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 ...

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation ...

New TKIs are available or in development that are more potent than imatinib for inhibiting Bcr-Abl and have a decreased potential for resistance. With these new agents, patients who develop ...

“Drugs that inhibit IDH1 and IDH2 can actually cause the cells to differentiate, and that is the technical term for convincing these cells to grow up,” says Dr. Tara Lin, Director of the Acute ...

5 Here, we describe a case of aggressive CAR+ T-cell lymphoma and investigate its lymphomagenesis. A 60-year-old man received the diagnosis of primary central nervous system lymphoma (PCNSL ...

The session began with Greeshma SS, the college librarian, who introduced Dr Priyanka and highlighted that September is leukaemia and lymphoma ... battle with acute myeloid leukaemia at 28 that ...

Acute chest syndrome is a serious complication of sickle cell disease. It involves symptoms like chest pain, cough, or fever and can be life threatening if not treated promptly. Sickle cell ...